Division of Nephrology, Department of Medicine, Schulich School of Medicine, University of Western Ontario, London, ON, Canada.
Kidney Clinical Research Unit, London Health Sciences Center, London, ON, Canada.
Nephrol Dial Transplant. 2019 Jul 1;34(7):1106-1111. doi: 10.1093/ndt/gfz004.
The risks and benefits of hemodialysis arteriovenous (AV) access surveillance have been debated since the introduction of AV access surveillance techniques. The debate is fuelled by the lack of robust, high-quality evidence with consistent and comparable patient-important outcomes. Additionally, there is a lack of clarity regarding the diagnostic cut points for AV access stenosis using the various surveillance techniques, questions about the appropriateness of the 'knee-jerk' response to intervention on a stenosis >50% regardless of the presence of clinical indicators and whether the intervention results in desired patient-important outcomes. The physiology of the AV access is complex considering the different hemodynamics within an AV fistula, which vary by time of dialysis, location, size of vessels and location of the stenosis. The current evidence suggests that the use of AV access surveillance in an AV fistula does detect more stenosis compared with clinical monitoring alone and leads to an increased number of procedures. It remains uncertain if that leads to improved patient-important outcomes such as prolonged AV fistula patency. Vascular access is an essential component of hemodialysis and further study is needed to clarify this long-standing debate. There needs to be better distinction between the strategies of vascular access surveillance, clinical monitoring with clinical indictors and preemptive intervention and their respective impacts on patient-important outcomes. Randomized controlled studies must be conducted with defined indications for intervention, reproducible methods of intervention and clinically important AV fistula and patient outcomes. The current guidelines need to be challenged and revised to permit these necessary studies to be done.
自动静脉(AV)通路监测技术问世以来,关于血液透析 AV 通路监测的风险和益处一直存在争议。这种争议的根源是缺乏强有力的高质量证据,无法提供具有一致性和可比性的重要患者结局。此外,使用各种监测技术时,对于 AV 通路狭窄的诊断切点存在不明确性,对于无论是否存在临床指征,对于狭窄程度>50%的病变是否应立即进行干预存在疑问,以及干预是否能带来期望的重要患者结局。考虑到 AV 瘘内的不同血流动力学,AV 通路的生理学非常复杂,这些血流动力学会随透析时间、位置、血管大小和狭窄部位而变化。目前的证据表明,与单独临床监测相比,在 AV 瘘中使用 AV 通路监测确实可以检测到更多的狭窄,并导致更多的操作。但尚不确定这是否会改善重要的患者结局,如延长 AV 瘘通畅时间。血管通路是血液透析的重要组成部分,需要进一步研究来澄清这一长期存在的争议。需要更好地区分血管通路监测策略、具有临床指征的临床监测和预防性干预及其对重要患者结局的各自影响。必须开展具有明确干预指征、可重复的干预方法和具有临床意义的 AV 瘘和患者结局的随机对照研究。目前的指南需要受到挑战和修订,以便进行这些必要的研究。